Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

31 mars 2026 15h44 HE | Source: Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome

Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.
19 mars 2026 08h53 HE | Source: Sol-Gel Technologies Ltd.

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
17 déc. 2025 07h00 HE | Source: Sol-Gel Technologies Ltd.

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
21 févr. 2023 07h30 HE | Source: Palvella Therapeutics

Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies

- Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 - - Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 - - Phase 2b...
28 mai 2020 16h08 HE | Source: Palvella Therapeutics

Palvella Therapeutics Completes $45 Million Series C Financing

Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome ...